Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EORTC CLTF 2018 | Checkpoint inhibitors for cutaneous lymphoma: the way of the future?

Christiane Querfeld • 27 Sep 2018
EORTC CLTF 2018
Cutaneous T-Cell Lymphoma Lymphoma Rare Diseases T-Cell Lymphoma Antibodies Checkpoint inhibitors

Could checkpoint inhibitors be the future of cutaneous T-cell lymphoma (CTCL) therapy? This exciting prospect is explored here by Christiane Querfeld, MD, PhD, from City of Hope, Duarte, CA, at the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland. Dr Querfeld discusses the potential of checkpoint inhibitors for CTCL, and highlights the areas of further study required to optimize our utilization of these agents.

More from Christiane Querfeld

1:12
Mogamulizumab-associated rash in patients with CTCL
Christiane Querfeld • 15 Oct 2021
2:15
CD47-blocking checkpoint inhibitor TTI-621 shows promising results for cutaneous T-cell lymphomas
Christiane Querfeld • 27 Sep 2018
3:00
Regulation of PD-L1 in cutaneous lymphoma by miRNAs
Christiane Querfeld • 27 Sep 2018
2:22
Antagomir for cutaneous T-cell lymphoma: promising trial results
Christiane Querfeld • 9 Dec 2017

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals